...
首页> 外文期刊>Italian Journal of Medicine >Generic - equivalent drugs use in internal and general medicine patients: distrust, confusion, lack of certainties or of knowledge? Part 2. Misconceptions, doubts and critical aspects when using generic drugs in the real world
【24h】

Generic - equivalent drugs use in internal and general medicine patients: distrust, confusion, lack of certainties or of knowledge? Part 2. Misconceptions, doubts and critical aspects when using generic drugs in the real world

机译:内科和普通科患者使用的仿制等效药物:不信任,困惑,缺乏确定性或知识?第2部分。在现实世界中使用仿制药时的误解,疑问和关键方面

获取原文
           

摘要

A lot of issues have been raised to argue that equivalent drugs may not work as well or at least the same as what the drug industry likes to call innovator products. Many doubts and biases are also reported in connection with the use of generic drugs. Doctors are mostly concerned about their efficacy, their tolerability, the quality and amount of active ingredients, their formulation or excipients, their packaging, their pharmaceutical form and their palatability. We describe the differences between prescribability (equivalence when prescribing a drug to a patient for the first time) and switchability (interchangeability of drugs for a patient already in treatment) considering the notions of average bioequivalence, population bioequivalence and individual bioequivalence as well as the usefulness of the U.S. Orange Book in the assessment of bioequivalence. Other key issues deserve attention, such as: duplicate applications for medicinal products, different salt forms, formulations used in the development of each medicinal product and excipients, product quality. Clinicians in collaboration with pharmacists and research pharmacologists have to find solutions for unanswered questions and unsolved doubts, by developing targeted studies, communication tools and shared guidelines.
机译:已经提出了许多问题,以争辩同等药物可能无法或至少与制药行业喜欢的创新产品一样不起作用。还报道了与使用仿制药有关的许多疑问和偏见。医生最关心的是它们的功效,耐受性,活性成分的质量和数量,制剂或赋形剂,包装,药物形式和适口性。考虑到平均生物等效性,群体生物等效性和个体生物等效性的概念以及有用性,我们描述了可处方性(首次向患者开药时的等效性)和可转换性(针对已在治疗的患者的药物互换性)之间的差异美国橙皮书评估生物等效性。其他关键问题值得关注,例如:药品的重复申请,不同的盐形式,每种药品和赋形剂开发中使用的配方,产品质量。临床医师必须与药师和研究药师合作,通过开发针对性的研究,交流工具和共享的指导方针,以解决未解决的问题和未解决的疑问。

著录项

相似文献

  • 外文文献
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号